BJ Hoogwerf, KB Doshi, D Diab - Vascular Health and Risk Management, 2008 - pubmedcentral.nih.gov Pramlintide is a synthetic version of the naturally occurring pancreatic peptide
called amylin. Amylin and pramlintide have similar effects on lowering
postprandial glucose, lowering postprandial glucagon and delaying gastric ... Cited by 8 - Related articles - BL Direct - All 7 versions
E Otto-Buczkowska, P Jarosz-Chobot, Ł … - Diabetologia Doświadczalna i Kliniczna, 2009 - viamedica.pl Address for correspondence: prof. dr hab. med. Ewa Otto-Buczkowska Samodzielny
Publiczny Szpital Kliniczny Nr 6 Śląskiego Uniwersytetu w Katowicach
Górnośląskie Centrum Zdrowia Dziecka im. Jana Pawła II w Katowicach ul. ... Related articles - View as HTML - All 2 versions
SL Norris, NJ Lee, B PharmD, S Severance, … - derp.ohsu.edu The purpose of this report is to make available information regarding the
comparative effectiveness and safety profiles of different drugs within
pharmaceutical classes. Reports are not usage guidelines, nor should they ... Related articles - View as HTML - All 2 versions
L Monnier - Nature Clinical Practice Endocrinology & Metabolism, 2007 - nature.com Louis Monnier is currently Professor of Endocrinology at the University of
Montpellier I and Head of the Department of Metabolic Diseases at the University
Hospital of Montpellier, France. He is a former secretary of the French ... Related articles - All 2 versions
RR Rubin, M Peyrot - The Diabetes Educator, 2009 - tde.sagepub.com Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit
Add to Technorati What's this? ... From the Johns Hopkins University School of
Medicine (Dr Rubin, Dr Peyrot) and Loyola College (Dr Peyrot), Baltimore, ... Related articles - All 2 versions
DM Huffman, GW McLean, MA Seagrove - Endocrine Practice - AACE Page 1. 1 Continuous Subcutaneous Pramlintide Infusion (CSPI) Therapy in Patients
with Type 1 Diabetes: Observations from a Pilot Study ... Related articles - All 3 versions
